Indication intelligence, analysis and sector perception

Mesoblast (USOTC: MBLTY) P2 cell therapy trial data has cardio-protective effect In patients with Advanced Heart Failure.

September 30, 2015 9:13am

USOTC: MBLTY closed at $12.39, the share pricing should "awaken" as low volume moves the needle - BUY

Mesoblast Limited (ASX: MSB; USOTC :MBLTY) P2 trial results of its lead product candidate for the treatment of chronic heart failure (CHF) were presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America in National Harbor, MD, USA held from 26-29 September.

The results showed that Mesoblast's mesenchymal precursor cell (MPC) therapy had the greatest cardio-protective effect in the subset of patients with more advanced heart failure.

The Bottom Line: The post-hoc analysis performed in 30 patients who had been randomized to receive either placebo or a single administration of 150 million MPCs (MPC-150-IM)results suggest that patients with advanced heart failure may be an optimal target population for treatment with Mesoblast's MPC therapy.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.